Scarica l'app Stockscreener
18.85
4.59%
-0.94
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
CAPR Stock Eyes 1st Weekly Gain In 5 Weeks: Capricor’s DMD Therapy Faces FDA Panel Review Next Week, Retail Sees 'Excellent Opportunity' - Stocktwits
Capricor Therapeutics (NASDAQ:CAPR) Share Price Crosses Below Two Hundred Day Moving AverageHere's Why - MarketBeat
S&P 500, Dow, Nasdaq Futures Climb As Trump Says Iran Ceasefire Holds Despite Fresh Hormuz Tensions: IREN, CRWV, CAPR, TTD Stocks In Focus - Stocktwits
CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision - Stocktwits
Investors in Capricor Therapeutics, Inc. Should Contact The Gros - GuruFocus
CAPR Stock Sinks After-Hours: Capricor Launches Legal Fight Over DMD Therapy Rollout Ahead Of FDA Review - Stocktwits
Can Capricor Therapeutics’ (CAPR) FDA-Linked HQ Expansion Reshape Its Risk Profile And Strategic Flexibility? - Sahm
CAPR Stock Surged 17% Today — What’s Fueling The Rally? - Stocktwits
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
ETFs Investing in Capricor Therapeutics, Inc. Stocks - TradingView
News | Capricor signs San Diego’s largest biotech lease of the year - CoStar
CAPR Stock Draws Investor Attention After AAN Presentation For DMD Therapy - Stocktwits
Cantor Fitzgerald reiterates Overweight on Capricor stock at $62 By Investing.com - Investing.com Canada
Capricor Therapeutics, Inc. Files Form 8-K: Company Details, Stock Information, and Key SEC Disclosures (July 2026) - Minichart
Capricor Therapeutics (NASDAQ: CAPR) signs 171,000 sq ft San Diego HQ lease - Stock Titan
Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Below 200 Day Moving AverageTime to Sell? - MarketBeat
Michael T Maurer Net Worth (2026) - GuruFocus
Moderna, Takeda and Capricor on the verge of notching big drug approvals - Pharma Voice
Behavioral Patterns of CAPR and Institutional Flows - Stock Traders Daily
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - Stocktwits
Capricor Therapeutics Company Profile & Introduction - Moomoo
Price to earnings forward of Capricor Therapeutics, Inc. – NASDAQ:CAPR - TradingView
Capricor Therapeutics (CAPR) Gets a Buy from Cantor Fitzgerald - The Globe and Mail
Cantor Fitzgerald Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $62 - Moomoo
Cantor Fitzgerald reiterates Overweight on Capricor stock ahead of FDA decision - Investing.com Canada
Capricor Therapeutics (CAPR) Is Down 5.8% After FDA Adcom Set, Russell Exit NewsHas The Bull Case Changed? - Sahm
CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval - Stocktwits
Capricor falls as FDA sets up AdCom meeting to review Duchenne therapy - MSN
Capricor Therapeutics (CAPR) Stock Looks Overvalued As Its 442% Run Draws Focus - Sahm
Capricor Sinks After FDA Rejects Drug for Muscle Disease - MSN
Enterprise value to EBITDA forward of Capricor Therapeutics, Inc. – NASDAQ:CAPR - TradingView
Capricor Therapeutics (NASDAQ:CAPR) Is In A Strong Position To Grow Its Business - Moomoo
Capricor Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Q4 2025 Capricor Therapeutics Inc Earnings Call Transcript - GuruFocus
CAPRCapricor Therapeutics Inc Volatility & Greeks - Finviz
Capricor Therapeutics (CAPR) Could Be 58% Undervalued Following FDA Focus And Index Removal - Sahm
CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains - Stocktwits
(CAPR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Capricor Therapeutics, Inc. Financial Disclosures & Filings - TradingView
Capricor’s positive 5-year data for DMD treatment comes with a regulatory catch – CAPR stock slides 11% - MSN
July meeting date set for FDA, developer to talk deramiocel for DMD - Muscular Dystrophy News
CAPR Stock Hits Over 4-Month Low: Capricor Execs Cash In $1.5M As FDA Sets Stage For DMD Drug Review - Stocktwits
Securities Class Action Lawsuit Filed Against Capricor Therapeuti - The National Law Review
Form 4 Capricor Therapeutics Inc For: 29 June By Investing.com - Investing.com Nigeria
Capricor Therapeutics EVP Karen Krasney sells $732,158 in stock By Investing.com - Investing.com India
Capricor CFO Bergmann sells $732k in shares By Investing.com - Investing.com Australia
0.29%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):